PROTOCOL TITLE: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF FERRIC CARBOXYMALTOSE (US TRADE NAME: INJECTAFER) AS TREATMENT FOR HEART FAILURE WITH IRON DEFICIENCY
- Registry ID
- 1VIT15043
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Study type
- INTERVENTIONAL
- Sponsor
- AMERICAN REGENT, INC
- Start date
- 2017-08-17
- Last update
- 2017-07-17
Conditions
- ANEMIA
- IRON DEFICIENCY
- HEART FAILURE
Related clinical trials
- EFFICACY AND SAFETY OF NNC0487-0111 COMPARED TO PLACEBO ON MORBIDITY AND MORTALITY IN PEOPLE WITH HEART FAILURE WITH PRESERVED OR MILDLY REDUCED EJECTION FRACTION AND OBESITY (HF-POLARIS)
- A MULTI-CENTER, RANDOMIZED, PARTICIPANT- AND INVESTIGATOR- BLINDED, PLACEBO-CONTROLLED CROSSOVER STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF HJB647 IN PARTICIPANTS WITH CHRONIC STABLE HEART FAILURE WITH REDUCED OR MILDLY REDUCED EJECTION FRACTION (HFREF/HFMREF)
- ORAL L-CARNITINE SUPPLEMENTATION IN CARDIORENAL HEART FAILURE PATIENTS
- A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO INVESTIGATE THE EFFICACY, SAFETY, AND PK/ PD OF FINERENONE, IN ADDITION TO STANDARD-OF-CARE, IN PEDIATRIC PATIENTS, 6 MONTHS TO < 18 YEARS OF AGE WITH HEART FAILURE (HF) AND LEFT VENTRICULAR SYSTOLIC DYSFUNCTION (LVSD)
- A PHASE 3, SINGLE-ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE SAFETY OF FINERENONE IN ADDITION TO STANDARD OF CARE, IN PEDIATRIC HEART FAILURE PATIENTS, FROM BIRTH TO 18 YEARS OF AGE, WITH LEFT VENTRICULAR SYSTOLIC DYSFUNCTION (LVSD)
- A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY,
PHARMACOKINETICS, AND PRELIMINARY EFFICACY OF ALN-CFB, AN INVESTIGATIONAL SIRNA THERAPEUTIC AGAINST
COMPLEMENT FACTOR B, IN PARTICIPANTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA AND PERSISTENT ANEMIA ON
APPROVED C5-INHIBITOR THERAPY
View on source registry